A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies

Vaccine

Volumn 33, Issue 16, 2015, Pages 1981-1986

  Singh, Susheel K ^a,b   Roeffen, Will ^c   Andersen, Gorm ^b   Bousema, Teun ^c,d   Christiansen, Michael ^a   Sauerwein, Robert ^c   Theisen, Michael ^a,b  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

GLURP; Pfs48 45; Plasmodium falciparum; SMFA; Transmission blocking

Indexed keywords

ALUMINUM HYDROXIDE; BLOCKING ANTIBODY; CYSTEINE; MALARIA VACCINE; PLASMODIUM FALCIPARUM 48 45 EPITOPE R0.6C SUBUNIT PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; EPITOPE; HYBRID PROTEIN; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIMALARIAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PURITY; DRUG STABILITY; IMMUNOGENICITY; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN PURIFICATION; RAT; RODENT MALARIA; RODENT MODEL; STABLE EXPRESSION; VACCINATION; ANIMAL; CHEMISTRY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MALARIA, FALCIPARUM; TRANSMISSION;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; EPITOPES; GENE EXPRESSION; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RATS; RECOMBINANT FUSION PROTEINS;

EID: 84933180087     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.02.040     Document Type: Article

References (24)

1. Sinden R.E. A biologist's perspective on malaria vaccine development. Hum Vaccin 2010, 6(1):3-11.
2. mal ERACGoV A research agenda for malaria eradication: vaccines. PLoS Med 2011, 8(1):e1000398.
3. Carter R. Transmission blocking malaria vaccines. Vaccine 2001, 19(Mar (17-19)):2309-2314.
4. Vermeulen A.N., Ponnudurai T., Beckers P.J., Verhave J.P., Smits M.A., Meuwissen J.H. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J Exp Med 1985, 162(Nov (5)):1460-1476.
5. Vermeulen A.N., Roeffen W.F., Henderik J.B., Ponnudurai T., Beckers P.J., Meuwissen J.H. Plasmodium falciparum transmission blocking monoclonal antibodies recognize monovalently expressed epitopes. Dev Biol Stand 1985, 62:91-97.
6. Outchkourov N., Vermunt A., Jansen J., Kaan A., Roeffen W., Teelen K., et al. Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. J Biol Chem 2007, 282(Jun (23)):17148-17156.
7. Roeffen W., Teelen K., van As J., Vd Vegte-Bolmer M., Eling W., Sauerwein R. Plasmodium falciparum: production and characterization of rat monoclonal antibodies specific for the sexual-stage Pfs48/45 antigen. Exp Parasitol 2001, 97(1):45-49.
8. van Dijk M.R., Janse C.J., Thompson J., Waters A.P., Braks J.A., Dodemont H.J., et al. A central role for P48/45 in malaria parasite male gamete fertility. Cell 2001, 104(1):153-164.
9. Outchkourov N.S., Roeffen W., Kaan A., Jansen J., Luty A., Schuiffel D., et al. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci USA 2008, 105(11):4301-4305.
10. Kocken C.H., Jansen J., Kaan A.M., Beckers P.J., Ponnudurai T., Kaslow D.C., et al. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum. Mol Biochem Parasitol 1993, 61(Sep (1)):59-68.
11. Milek R.L., DeVries A.A., Roeffen W.F., Stunnenberg H., Rottier P.J., Konings R.N. Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells. Exp Parasitol 1998, 90(Oct (2)):165-174.
12. Milek R.L., Stunnenberg H.G., Konings R.N. Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 of the human malaria parasite Plasmodium falciparum in yeast. Vaccine 2000, 18(Jan (14)):1402-1411.
13. Milek R.L., Roeffen W.F., Kocken C.H., Jansen J., Kaan A.M., Eling W.M., et al. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli. Parasite Immunol 1998, 20(8):377-385.
14. Chowdhury D.R., Angov E., Kariuki T., Kumar N. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS ONE 2009, 4(7):e6352.
15. Theisen M., Roeffen W., Singh S.K., Andersen G., Amoah L., van de Vegte-Bolmer M., et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine 2014, 32(Mar (22)):2623-2630.
16. Theisen M., Soe S., Brunstedt K., Follmann F., Bredmose L., Israelsen H., et al. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 2004, 22(Mar (9-10)):1188-1198.
17. Holo H., Nes I.F. Transformation of Lactococcus by electroporation. Methods Mol Biol 1995, 47:195-199. 195-9.
18. Churcher T.S., Blagborough A.M., Delves M., Ramakrishnan C., Kapulu M.C., Williams A.R., et al. Measuring the blockade of malaria transmission-an analysis of the Standard Membrane Feeding Assay. Int J Parasitol 2012, 42(Oct (11)):1037-1044.
19. MacArthur M.W., Thornton J.M. Influence of proline residues on protein conformation. J Mol Biol 1991, 218(Mar (2)):397-412.
20. Bousema T., Okell L., Felger I., Drakeley C. Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nat Rev Microbiol 2014, 12(12):833-840.
21. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364(9443):1411-1420.
22. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27(43):5956-5963.
23. Lell B., Agnandji S., von Glasenapp I., Haertle S., Oyakhiromen S., Issifou S., et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS ONE 2009, 4(10):e7611.
24. Lousada-Dietrich S., Jogdand P.S., Jepsen S., Pinto V.V., Ditlev S.B., Christiansen M., et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2-a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011, 29(Apr (17)):3284-3292.